

Bruker to acquire EliTechGroup

March 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about \$940 million) in cash, excluding EliTech's clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.

EliTechGroup is headquartered in Turin, Italy, and employs more than 500 people. Its molecular diagnostic business accounts for the majority of the revenues to be acquired. EliTech offers two sample-to-answer molecular diagnostic systems, InGenius and BeGenius, and assays for pathogens and viral disease, as well as niche biomedical systems and microbiology products. Its major R&D and operations sites are in Italy, the United States, France, and Germany.

Upon closing, EliTech is expected to be a standalone business within Bruker's microbiology and infection diagnostics division, as a part of the Bruker Calid group.

[Bruker Corp.](#), 978-663-3660

[EliTechGroup](#), +39 011 976191